Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cidan capsule is an orally administered, China-marketed traditional Chinese medicine formula used as an adjunctive antineoplastic treatment for primary liver cancer, including hepatocellular carcinoma. It is a heterogeneous medicinal mixture containing artificial bezoar, strychnos powder, borneol, and botanical or natural-material preparations including zedoary rhizome, Cremastra appendiculata pseudobulb, Brucea javanica seed, beehive, Bombyx batryticatus, Salvia miltiorrhiza root, Astragalus root, and Angelica. Its proposed anticancer activity is multi-component and multi-target rather than attributable to a single defined active pharmaceutical ingredient; preclinical studies report reduced tumor-cell proliferation, apoptosis induction, cell-cycle arrest, and reduced COX-2 and VEGF expression. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cidan-herbal-capsule))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cidan capsule.